Role of erlotinib in the management of pancreatic cancer
Pancreatic cancer is a largely chemo-resistant disease with a poor prognosis. Despite the adoption of gemcitabine monotherapy as a standard of care, outcomes remain poor. Until recently randomized phase III studies have not demonstrated superiority of various cytotoxic combinations or a number of th...
| Main Authors: | , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Dove Medical Press
2006
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1936363/ |